Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops SEL24/MEN1703, a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia. In addition, the company's early pipeline candidates include candidates in the areas of kinases, synthetic lethality, immunometabolism, and immuno-oncology. It has collaborations with BioNTech SE to advance small molecule programs to target immune modulation in cancer and other disease areas; Exelixis Inc. for the development of targeted therapies based on Ryvu's STING agonist technology. The company was formerly known as Selvita S.A. and changed its name to Ryvu Therapeutics S.A. in October 2019. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.